BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/12/2020 10:38:05 AM | Browse: 699 | Download: 1355
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 54337
Country United States
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
Manuscript Source Invited Manuscript
All Author List Sakti Chakrabarti, Carrie Y Peterson, Deepika Sriram and Amit Mahipal
Funding Agency and Grant Number
Corresponding Author Sakti Chakrabarti, MD, Associate Professor, Division of Hematology/Oncology, Medical College of Wisconsin, No. 8701, Watertown Plank Road, Milwaukee, WI 53226, United States. schakrabarti@mcw.edu
Key Words Adjuvant; Circulating tumor DNA; Immunoscore; Minimally invasive; Neoadjuvant; FOxTROT
Core Tip Although the majority of patients with colon cancer are diagnosed in an early stage, cancer recurrence after initial curative therapy is frequent, underscoring the need for novel approaches. The challenges in the current treatment paradigm include the lack of precise patient selection tools for adjuvant therapy, disabling toxicities, and modest efficacy of the adjuvant therapies. Herein we provide a contemporaneous appraisal of the early stage colon cancer treatment and discuss how evolving technologies, including circulating tumor DNA, can potentially transform the standard of care.
Publish Date 2020-08-12 09:10
Citation Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, future directions. World J Gastrointest Oncol 2020; 12(8): 808-832
URL https://www.wjgnet.com/1948-5204/full/v12/i8/808.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i8.808
Full Article (PDF) WJGO-12-808.pdf
Full Article (Word) WJGO-12-808.docx